-
1.发明公开
公开(公告)号：EP4549618A1
公开(公告)日：2025-05-07
申请号：EP24207979.6
申请日：2024-10-22
Applicant: BASF SE
Inventor： VOSSEN, Marcus , ERNST, Martin , STOCK, Christoph , HARNHAUSEN, Sina , XIONG, Jiawen , HUEFFER, Stephan , KRUEGER, Marco , WEISS, Thomas
Abstract: A process for the preparation of amines comprising the following steps:
(a) providing hydrogen with a molar share of deuterium ≤ 100 ppm, preferably in the range of from 10 to 95 ppm, more preferably in the range of from 15 to 90 ppm, most preferably in the range of from 20 to 80 ppm, especially in the range of from 30 to 75 ppm, based on the total hydrogen content, by electrolysis of water using electrical power generated at least in part from non-fossil energy,
(b) reacting the hydrogen from step (a) with nitrogen to form ammonia,
(c) reacting the ammonia from step (b) with a nitrile compound or hydrogen cyanide (I)
R-CN (I)
in the presence of hydrogen from step (a) to form the corresponding amine (II)
RCH 2 -NH 2 (II).-
2.发明公开MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS 审中-公开KRISTALLINES系统麻醉剂美沙酮KIMPONENTEN MIT NILOTINIB UNDAUSGEWÄHLTENCO-KRISTALL-FORMERN
公开(公告)号：EP2909191A1
公开(公告)日：2015-08-26
申请号：EP13783008.9
申请日：2013-10-16
Applicant: BASF SE
Inventor： CHIODO, Tiziana , HAFNER, Andreas , HINTERMANN, Tobias , SALVADOR, Beate , SZELAGIEWICZ, Martin , BLATTER, Fritz , RöDEL, Eva , VOSSEN, Marcus
IPC: C07D401/14 , A61K31/506 , A61P35/02
CPC classification number: C07D401/14
Abstract: The present invention relates to crystalline materials comprising nilotinib and a carboxylic acid, carboxylic acid ester, carboxylic acid amide or sulfonic acid as a co-crystal former, and to pharmaceutical compositions comprising said materials. The invention also relates to processes for preparing said crystalline materials and to methods of using said crystalline materials to treat a disease condition in which tyrosine kinase inhibition is beneficial.
Abstract translation: 本发明涉及包含尼罗替尼和羧酸，羧酸酯，羧酸酰胺或磺酸作为共晶体形成剂的结晶材料以及包含所述材料的药物组合物。 本发明还涉及制备所述结晶材料的方法以及使用所述结晶材料治疗其中酪氨酸激酶抑制是有益的疾病状况的方法。
-
3.发明授权
公开(公告)号：EP2861589B1
公开(公告)日：2017-05-17
申请号：EP13804937.4
申请日：2013-06-13
Applicant: BASF SE
Inventor： CHIODO, Tiziana , HAFNER, Andreas , HINTERMANN, Tobias , SALVADOR, Beate , SZELAGIEWICZ, Martin , BLATTER, Fritz , SIEBENHAAR, Bernd , VOSSEN, Marcus
IPC: C07D417/12 , A61K31/506 , A61P35/02
CPC classification number: C07D417/12 , A61K31/506 , C07B2200/07 , C07B2200/13 , C07C35/12 , C07C47/58 , C07C65/03 , C07C69/84 , C07D213/82 , C07D309/40 , A61K2300/00
-
公开(公告)号：EP3160963A1
公开(公告)日：2017-05-03
申请号：EP15731329.7
申请日：2015-06-24
Applicant: BASF SE
Inventor： VIERTELHAUS, Martin , CHIODO, Tiziana , SALVADOR, Beate , VOSSEN, Marcus , HAFNER, Andreas , HINTERMANN, Tobias , SZELAGIEWICZ, Martin , BLATTER, Fritz
IPC: C07D417/12 , A61K31/506
CPC classification number: C07D417/12
Abstract: The present invention primarily relates to multicomponent crystals comprising a compound of formula 1 and a second compound selected from the group consisting of menthol and vanillin. The invention is further related to pharmaceutical compositions comprising such multicomponent crystals. Furthermore, the invention relates to processes for preparing said multicomponent crystals. The invention also relates to several aspects of using said multicomponent crystals or pharmaceutical compositions to treat a disease.
Abstract translation: 本发明主要涉及包含式1化合物和选自薄荷醇和香草醛的第二化合物的多组分晶体。 本发明还涉及包含这种多组分晶体的药物组合物。 此外，本发明涉及制备所述多组分晶体的方法。 本发明还涉及使用所述多组分晶体或药物组合物治疗疾病的几个方面。
-
公开(公告)号：EP3080141A1
公开(公告)日：2016-10-19
申请号：EP14809636.5
申请日：2014-12-09
Applicant: BASF SE
Inventor： CHIODO, Tiziana , SALVADOR, Beate , VOSSEN, Marcus , HAFNER, Andreas , HINTERMANN, Tobias , SZELAGIEWICZ, Martin , BLATTER, Fritz , VIERTELHAUS, Martin , WEISHAAR, Walter
CPC classification number: A61K31/58 , A61K9/14 , C07B2200/13 , C07J43/003
Abstract: Combinations of (3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-yl acetate (Abiraterone acetate) with acidic substances such as citric acid, ascorbic acid, methyl-4-hydroxy benzoate, saccharin, vanillic acid, adipic acid, maleic acid, malic acid, tartaric acidare useful as pharmaceutical preparations and show improved properties such as aqueous solubility and dissolution kinetics, especially in the form of cocrystals or their combination with a suitable acid.
-
Patent Agency Ranking
公开(公告)号：EP3024831A2
公开(公告)日：2016-06-01
申请号：EP14741880.0
申请日：2014-07-22
Applicant: BASF SE
Inventor： HAFNER, Andreas , BLATTER, Fritz , SZELAGIEWICZ, Martin , SIEBENHAAR, Bernd , CHIODO, Tiziana , HINTERMANN, Tobias , SALVADOR, Beate , VOSSEN, Marcus
IPC: C07D417/12
CPC classification number: C07D417/12 , C07C55/12 , C07D213/80 , C07D275/06
Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
Abstract translation: 本发明主要涉及达沙替尼的盐，其中盐是无定形形式。 本文所述的盐优选包含式1的化合物的阳离子和选自戊二酸，烟酸和糖精的第二化合物的阴离子。 本发明进一步涉及包含这种盐的药物组合物。 此外，本发明涉及制备所述盐的方法。 本发明还涉及使用所述盐或药物组合物治疗疾病的几个方面。
-
7.发明公开
公开(公告)号：EP2861589A2
公开(公告)日：2015-04-22
申请号：EP13804937.4
申请日：2013-06-13
Applicant: BASF SE
Inventor： CHIODO, Tiziana , HAFNER, Andreas , HINTERMANN, Tobias , SALVADOR, Beate , SZELAGIEWICZ, Martin , BLATTER, Fritz , SIEBENHAAR, Bernd , VOSSEN, Marcus
IPC: C07D417/12 , A61K31/506 , A61P35/00
CPC classification number: C07D417/12 , A61K31/506 , C07B2200/07 , C07B2200/13 , C07C35/12 , C07C47/58 , C07C65/03 , C07C69/84 , C07D213/82 , C07D309/40 , A61K2300/00
Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula 1 (INN: Dasatinib) and a second compound selected from methyl-4-hydroxybenzoate, or nicotinamide, or ethyl gallate, or methyl gallate, or propyl gallate, or ethyl maltol or vanillin, or men- thol, or (1R,2S,5R)-(-)-menthol,as well as to a process for obtaining the same.
-
公开(公告)号：EP3024830A2
公开(公告)日：2016-06-01
申请号：EP14741630.9
申请日：2014-07-22
Applicant: BASF SE
Inventor： HAFNER, Andreas , BLATTER, Fritz , SZELAGIEWICZ, Martin , SIEBENHAAR, Bernd , CHIODO, Tiziana , HINTERMANN, Tobias , SALVADOR, Beate , VOSSEN, Marcus
IPC: C07D417/12 , A61K31/506
CPC classification number: C07D417/12 , C07B2200/13 , C07D275/06
Abstract: The present invention primarily relates to molecular crystalline substances, preferably salts of Dasatinib in crystalline form, comprising a compound of formula 1, preferably a cation of a compound of formula 1, and a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin, preferably an anion thereof. The Invention is further related to pharmaceutical compositions comprising such a substance. Furthermore, the Invention relates to processes for preparing said substances. The invention also relates to several aspects of using said substances or pharmaceutical compositions to treat a disease.
Abstract translation: 本发明主要涉及分子结晶物质，优选结晶形式的达沙替尼盐，其包含式1化合物，优选式1化合物的阳离子和选自戊二酸，烟酸的第二化合物 和糖精，优选其阴离子。 本发明进一步涉及包含这种物质的药物组合物。 此外，本发明涉及制备所述物质的方法。 本发明还涉及使用所述物质或药物组合物治疗疾病的若干方面。
-
9.发明公开MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING DEFERASIROX AND ISONICOTINAMIDE AND A PROCESS FOR THE PREPARATION THEREOF 有权结晶多组分系统和拉罗司ISONIKOTINAMID及其制造方法
公开(公告)号：EP2880019A1
公开(公告)日：2015-06-10
申请号：EP13750525.1
申请日：2013-08-05
Applicant: BASF SE
Inventor： HAFNER, Andreas , BLATTER, Fritz , RÖDEL, Eva , SZELAGIEWICZ, Martin , CHIODO, Tiziana , HINTERMANN, Tobias , SALVADOR, Beate , VOSSEN, Marcus
IPC: C07D249/08 , A61K31/4196 , A61P7/00
CPC classification number: C07D213/81 , C07B2200/13 , C07D249/08
Abstract: The present invention refers to a multicomponent crystalline system (co-crystal) comprising a compound of formula (1) (4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid; INN:Deferasirox) formula (1) and a compound of formula (2) (Isonicotinamide; pyridine-4-carboxamide) formula (2), as well as to a process for obtaining the same.
-
10.发明公开
公开(公告)号：EP4549433A1
公开(公告)日：2025-05-07
申请号：EP24207976.2
申请日：2024-10-22
Applicant: BASF SE
Inventor： VOSSEN, Marcus , STOCK, Christoph , ERNST, Martin , MOELLER, Malte , PUHL, Michael , KUNSMANN-KEITEL, Dagmar Pascale , HARHAUSEN, Sina , XIONG, Jiawen , HUEFFER, Stephan , KRUEGER, Marco , WEISS, Thomas
IPC: C07D307/06 , C07D307/08 , C07D307/12 , C07D307/36 , C07D307/44 , C07C29/132 , C07C31/18 , C07C31/20 , C07C31/26 , C07H15/04 , C01B3/02 , C25B1/04
Abstract: A process for the preparation of a hydrogenation product of a carbohydrate or furfural comprising the following steps:
(a) providing hydrogen with a molar share of deuterium ≤ 100 ppm, based on the total hydrogen content, by electrolysis of water using electrical power generated at least in part from non-fossil energy,
(b) at least partially hydrogenating a carbohydrate or furfural to form the corresponding hydrogenation product of the carbohydrate or furfural.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.015 seconds)
